Analysis of the value of intestinal flora reconstruction in the treatment of alcoholic liver disease with chronic diarrhea
-
摘要: [目的]：探讨酒精性肝病肠道菌群重建治疗慢性腹泻的价值。[方法]采用前瞻性研究方法，选择2015年3月~2015年8月在我院诊治的酒精性肝病伴慢性腹泻患者90例，根据信封随机抽签原则分为治疗组50例与对照组40例，对照组服用蒙脱石散治疗，治疗组接受双歧杆菌四联活菌片联合谷氨酰胺颗粒治疗，2组都以2周为1个疗程，治疗观察1个疗程。[结果]从总有效率方面分析，治疗组和对照组分别是96.0%与77.5%，治疗组显著高于对照组（P<0.05）。对照组治疗前后的大肠杆菌、双歧杆菌、乳酸菌与肠球菌含量比较差异无统计学意义（P>0.05），而治疗组治疗后的双歧杆菌、乳酸菌含量明显增加，而大肠杆菌、肠球菌含量明显降低，两两比较差异有统计学意义（P<0.05）。治疗组与对照组治疗后的血清ALT与AST值都明显低于治疗前（P<0.05），组间比较差异无统计学意义（P>0.05）。治疗组与对照组治疗后的血清TNF-ɑ含量分别为（43.14±19.55） ng/ml和（65.25±20.81） ng/ml，明显低于治疗前的（92.94±15.39） ng/ml和（92.81±16.11） ng/ml （P<0.05），且治疗组明显低于对照组（P<0.05）。[结论]酒精性肝病肠道菌群重建治疗慢性腹泻能提高粪便中双歧杆菌和乳酸杆菌含量，改善患者的肝功能，促进临床疗效的提高，其作用机制可能与调节炎性因子的表达有关。Abstract: [Objective]:To explore the values of intestinal flora reconstruction in the treatment of alcoholic liver disease with chronic diarrhea.[Methods] A prospective study was conducted.From March 2015 to August 2015, 90 alcoholic liver disease with chronic diarrhea patients were selected in our hospital for treatment.All the patients were equally randomized into treatment group of 50 patients and control group of 40 patients according to the envelope principles.The control group was treated with Smecta treatment, while the treatment group received Bifidobacterium Tetravaccine tablets combined with glutamine granules treatment.Two weeks were a course of treatment, and the treatment cycles were 2 courses.[Results] The total effective rate of the treatment group and the control group were 96.0% and 77.5%, respectively, which was significantly higher in the treatment group than that of the control group(P<0.05).The Escherichia coli, Bifidobacterium, Lactobacillus and Enterococcus contents in the control group were insignificantly different compared before and after the treatment(P>0.05), while the Bifidobacterium, Lactobacillus contents were significantly increased after treatment in treatment group, the Escherichia coli and Enterococcus contents were significantly decreased(P<0.05).The serum ALT and AST values in the treatment group and control group after treatment were significantly lower than before treatment(P<0.05), there was no significant difference compared between the groups(P>0.05).The serum TNF-ɑ levels in the treatment group and control group after treatment were(43.14±19.55) ng/ml and (65.25±20.81) ng/ml, which were significantly lower than those before treatment of (92.94±15.39) ng/ml and (92.81±16.11) ng/ml(P<0.05), and the treatment group was significantly lower than that of the control group(P<0.05).[Conclusion] The intestinal flora reconstruction in the treatment of alcoholic liver disease with chronic diarrhea can improve Bifidobacterium, Lactobacillus content, improve liver function of patients, and improve the clinical curative effect.Its mechanism may be related to regulating the expression of inflammatory cytokines.
-
Key words:
- alcoholic liver disease /
- intestinal flora /
- chronic diarrhea /
- inflammatory factors /
- Bacillus
-
-
[1] 郑锋玲, 骆欢欢.肠道菌群与慢性肝损伤关系的研究进展[J].广东医学, 2015, 2(14):2269-2271.
[2] 梁淑文, 王晓英, 屈昌民, 等.非酒精性脂肪性肝病患者胰岛素抵抗与肠道菌群失调相关性研究[J].中国医药, 2016, 11(1):83-86.
[3] Snider E J, Freedberg D E, Abrams J A.Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma[J].Dig Dis Sci, 2016, 61(8):2217-2225.
[4] Koh J C, Loo W M, Goh K L, et al.Asian Consensus on the relationship between Obesity and Gastrointestinal and Liver Diseases[J].J Gastroenterol Hepatol, 2016, 5(24):240-244.
[5] 邱萍, 李相, 孔德松, 等.酒精性肝病发病机制研究的新进展[J].中国药理学通报, 2014, 30(2):160-163.
[6] Schulz C, Schütte K, Kropf S, et al.RiMINI-the influence of rifaximin on minimal hepatic encephalopathy(MHE)and on the intestinal microbiome in patients with liver cirrhosis:study protocol for a randomized controlled trial[J].Trials, 2016, 17(1):111-114.
[7] Ling Q, Xu X, Wang B, et al.The Origin of New-Onset Diabetes After Liver Transplantation:Liver, Islets, or Gut?[J].Transplantation, 2016, 100(4):808-813.
[8] 刘慧, 朱文娅, 孙涛.非酒精性脂肪性肝病肠道菌群变化及其与胰岛素抵抗的关系[J].中国临床医生, 2014, 22(5):31-33.
[9] 李琳, 李岩.肠道菌群失调与功能性腹泻[J].胃肠病学和肝病学杂志, 2014, 23(7):723-726.
[10] Castagnola E, Ruberto E, Guarino A.Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000[J].World J Gastroenterol, 2016, 22(25):5853-5866.
[11] Kuno T, Hirayama-Kurogi M, Ito S, et al.Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice[J].Mol Pharm, 2016, 13(8):2691-2701.
[12] 陈丽娜, 沈丽, 王敏莉, 等.益生菌对肠易激综合征和炎症性肠病的作用[J].胃肠病学和肝病学杂志, 2014, 23(5):584-587.
[13] Shin C M, Kim N, Kim Y S, et al.Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats:Pilot Study[J].Gut Liver, 2016, 7(27):8177-8181.
[14] 臧月, 王生, 刘楠, 等.肠道菌群失调介导酒精性肝病发生发展的机制研究进展[J].中国药理学通报, 2016, 32(4):451-455.
[15] Iqbal S, Quigley M.Progress in Our Understanding of the Gut Microbiome:Implications for the Clinician[J].Curr Gastroenterol Rep, 2016, 18(9):49-54.
[16] Reid D T, McDonald B, Khalid T, et al.Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease[J].Biochim Biophys Acta, 2016, 1862(7):1337-1344.
[17] 刘志威, 王学群, 李甜甜.溃疡性结肠炎患者肠道菌群变化的临床意义[J].胃肠病学和肝病学杂志, 2016, 25(5):554-556.
[18] Kedia S, Rampal R, Paul J, et al.Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India[J].J Gastroenterol, 2016, 51(7):660-671.
[19] 郑啼婴, 李瑜元, 聂玉强, 等.肠道菌群对非酒精性脂肪性肝病病变程度的影响[J].广州医科大学学报, 2016, 44(1):9-13.
[20] 易宏淦, 臧梦雅, 吴志远, 等.慢性肠道炎症促进肝癌的发展[J].中国比较医学杂志, 2015, 22(5):1-4.
[21] Blanton L V, Charbonneau M R, Salih T, et al.Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children[J].Science, 2016, 351(62):78-84.
[22] 周达, 范建高.肠道菌群-SCFAs在代谢性疾病中的作用研究[J].胃肠病学和肝病学杂志, 2016, 25(3):330-332.
[23] 朱孟华, 史立军.肠道菌群在肠易激综合征中的病理生理作用[J].胃肠病学和肝病学杂志, 2016, 25(1):105-107.
-
计量
- 文章访问数: 277
- PDF下载数: 341
- 施引文献: 0
下载: